$1.650
-0.085 (-5.17%)At close
MENS Comparative Benchmarking
In the context of the broader market, MENS competes directly with industry leaders such as IPHA and NBP. With a market capitalization of $125.45M, it holds a significant position in the sector. When comparing efficiency, MENS's gross margin of N/A stands against IPHA's 66.04% and NBP's N/A. Such benchmarking helps identify whether Jyong Biotech Ltd is trading at a premium or discount relative to its financial performance.
Jyong Biotech Ltd Financial Performance
Jyong Biotech has reported consistent losses, with a net income of -3,419,000 USD in Q4 2025 and a current ratio of only 0.45, indicating liquidity issues. The company has a negative price-to-book ratio of -5.73, suggesting it is trading below its liquidation value.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.